If WYE were to launch an authorized generic, how would it affect the assessment of damages in the event WYE eventually prevails in the patent trial? Would an AG launch preclude collecting treble damages or lessen the likelihood of such to a significant degree? T.i.a. Dew
Analysts at UBS think that Teva has already shipped a 3-4 months supply.
Here's ML take: >Merrill Lynch's Gregg Gilbert explains, "At this time, we are not making any changes to our model (2007 earnings per share of $2.34, 2008 earnings per share of $2.56). We had earlier estimated that generic Protonix could contribute up to $184 million in sales and $0.11 per share earnings. Presently, neither Sun nor Wyeth (as an authorized generic) has launched, and our prior estimates could be conservative depending on the duration of Teva’s “sole” exclusivity." One reasons for Merrill holding back, and its "Neutral" rating on the shares, is a lack of financial clarity regarding the drug. "Management believes that Teva had a “relatively full” generic Protonix launch, but did not provide any quantitative color.<
Market Data 
Markets 
AI
